Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia
Key facts
- Who runs it
- Reema Padia
- Where
- Pittsburgh, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 1/2
- People taking part
- 65 people enrolled
- Started
- 18 Nov 2020
- Ended
- 17 May 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Famotidine
- Speech Language Therapy
- Record updated
- 20 July 2025
- Why it stopped
- Slow recruitment due to few eligible patients
Who can take part
- Age
- 0 months to 6 months
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Pediatric patients ages 0 to 6 months who do need meet the criteria at the initial appointment for supraglottoplasty
- Seen in University of Pittsburgh Medical Center (UPMC) Children's Hospital of Pittsburgh (CHP) Otolaryngology Department
- Laryngomalacia without prolonged (>20 seconds) cyanosis, apnea, nor failure to thrive
Who cannot take part
- Patients with symptoms that necessitate surgery
- Patients with a prior cardiac surgery
- Patients with lung disease
- Laryngomalacia with prolonged (>20 seconds) cyanosis, apnea, and failure to thrive
- Patients with a syndrome
- Patients with AST prescribed prior to the initial otolaryngology consult
- Children over the age of 6 months old will be excluded from participation
- Premature infants (<37 weeks gestation)
- Sleep induced laryngomalacia
- Patients with craniofacial abnormalities
- Patients with additional airway abnormalities, seen before or at consult
Where in United States
- UPMC Children's Hospital of PittsburghPittsburgh, United States
About the trial
What the trial wants to find out
Laryngomalacia (LM) is the most common cause of stridor in infants. Symptoms of gastroesophageal reflux (GER) are often seen in the setting of LM; therefore, acid suppression therapy (AST) has been empirically used in the management of this disorder. The investigators recently performed a retrospective chart review assessing improvement of airway and dysphagia symptoms, weight gain, and need for surgery with AST. It was found that there was a similar improvement between LM severity groups and most patients received AST (96.6%). It is unclear if these improvements are due to AST or natural resolution of the disease. With heightened concerns of side effects related to AST in infants, particularly among those born prematurely, judicious use of these medications is needed. The investigators are now performing a prospective study looking at the outcome differences in patients with laryngomalacia who are evaluated by speech language therapy (SLP) alone versus those with SLP evaluation and acid suppression therapy (famotidine).
The 2 groups in the trial
- Speech Language Therapy AloneTreatment being tested
Patients in this group will receive a routine swallowing evaluation by a speech language pathologist. Patient caregivers will fill out the Infant Gastroesophageal Reflux Questionnaire (I-GERQ-R) and the Pittsburgh Airway Symptom Score (PASS) the day of the appointment and at the 3-month follow up appointment.
Treatment: Speech Language Therapy
- Speech Language Therapy and Acid Suppression TherapyExisting treatment, for comparison
Patients in this group will receive a routine swallowing evaluation by a speech language pathologist and famotidine (acid suppression therapy). Patient caregivers will fill out the Infant Gastroesophageal Reflux Questionnaire (I-GERQ-R) and the Pittsburgh Airway Symptom Score (PASS) the day of the appointment and at the 3-month follow up appointment.
Treatment: Famotidine and Speech Language Therapy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Record updated
- 20 July 2025